Early effective treatment may protect from cognitive decline in paediatric multiple sclerosis

Cognitive impairment (CI) is a critical feature for patients with childhood or juvenile multiple sclerosis (MS). To promote the understanding of CI and to address the impact of different pharmacological treatment strategies on cognitive performance in this patient group. A cohort of 19 patients with...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	European journal of paediatric neurology Ročník 23; číslo 6; s. 783 - 791
Hlavní autori:	Johnen, A., Elpers, C., Riepl, E., Landmeyer, N.C., Krämer, J., Polzer, P., Lohmann, H., Omran, H., Wiendl, H., Göbel, K., Meuth, S.G.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England Elsevier Ltd 01.11.2019
Predmet:	Adjuvants, Immunologic - therapeutic use Adolescent Child Cognition Cognitive Dysfunction - etiology Cognitive Dysfunction - prevention & control Cohort Studies Disease-modifying drugs Executive Function - drug effects Female Humans Interferon beta-1a - therapeutic use Juvenile multiple sclerosis Male Multiple Sclerosis - complications Multiple Sclerosis - drug therapy Neuropsychological Tests Neuropsychology Paediatric multiple sclerosis Treatment Treatment Outcome Juvenile multiple sclerosis Cognition Treatment Neuropsychology Paediatric multiple sclerosis Disease-modifying drugs
ISSN:	1090-3798, 1532-2130, 1532-2130
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!